Effects of the mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures

Neuropsychopharmacology

Volumn 40, Issue 4, 2015, Pages 957-965

  Peciña, Marta ^a   Love, Tiffany ^a   Stohler, Christian S ^b   Goldman, David ^c   Zubieta, Jon Kar ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; DOPAMINE; GLYCINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR 1; NEUROTRANSMITTER; OPIATE; OPIATE RECEPTOR; PLACEBO; UNCLASSIFIED DRUG; CARFENTANIL; DOPAMINE RECEPTOR BLOCKING AGENT; FENTANYL; NARCOTIC ANALGESIC AGENT; RACLOPRIDE;

ADULT; AFFECT; AMINO ACID SUBSTITUTION; AMYGDALOID NUCLEUS; ANALGESIA; ANTERIOR CINGULATE; ANTERIOR INSULA; ARTICLE; COGNITION; CONTROLLED STUDY; EMOTION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD DISORDER; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NUCLEUS ACCUMBENS; PAIN; PERSONALITY; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOPHYSICS; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; STIMULUS; SUBGENUAL ANTERIOR CINGULATE CORTEX; THALAMUS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; GENOTYPE; MYALGIA; PAIN MEASUREMENT; PERSONALITY TEST; PHYSICAL STIMULATION; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGY;

ADULT; AFFECT; ANALGESICS, OPIOID; DOPAMINE ANTAGONISTS; FEMALE; FENTANYL; GENOTYPE; HUMANS; MALE; MYALGIA; PAIN MEASUREMENT; PERSONALITY; PERSONALITY INVENTORY; PHYSICAL STIMULATION; PLACEBO EFFECT; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, OPIOID, MU;

EID: 84925532737     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.272     Document Type: Article

References (58)

1. Benedetti F (2013). Placebo and the new physiology of the doctorpatient relationship. Physiol Rev 93: 1207-1246.
2. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK (2005). Neurobiological mechanisms of the placebo effect. J Neurosci 25: 10390-10402.
3. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309-369.
4. Bisgaard T, Klarskov B, Rosenberg J, Kehlet H (2001). Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain 90: 261-269.
5. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95: 9608-9613.
6. Canli T (2004). Functional brain mapping of extraversion and neuroticism: learning from individual differences in emotion processing. J Pers 72: 1105-1132.
7. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B (2006a). Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105: 334-337.
8. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH et al (2006b). Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50: 787-792.
9. Costa PT Jr., McCrae RR (1980). Influence of extraversion and neuroticism on subjective well-being: happy and unhappy people. J Pers Soc Psychol 38: 668-678.
10. Costa PT, McCrae RR (1992). Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory Professional Manual. Psychological Assessment Resources: Odessa, FL.
11. Friston KJ, Worsley KJ, Frackowiak RS, Mazziotta JC, Evans AC (1994). Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp 1: 210-220.
12. Gear RW, Aley KO, Levine JD (1999). Pain-induced analgesia mediated by mesolimbic reward circuits. J Neurosci 19: 7175-7181.
13. Goubert L, Crombez G, Van Damme S (2004). The role of neuroticism, pain catastrophizing and pain-related fear in vigilance to pain: a structural equations approach. Pain 107: 234-241.
14. Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB et al (2012). Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS ONE 7: e48135.
15. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK (2007). Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 27: 10000-10006.
16. Hodgkinson CA, Yuan Q, Xu K, Shen PH, Heinz E, Lobos EA et al (2008). Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 43: 505-515.
17. Horvitz JC (2000). Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 96: 651-656.
18. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H et al (2013). Response of the mu-opioid system to social rejection and acceptance. Mol Psychiatry 18: 1211-1217.
19. Johnson SW, North RA (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483-488.
20. Kelley JM, Lembo AJ, Ablon JS, Villanueva JJ, Conboy LA, Levy R et al (2009). Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med 71: 789-797.
21. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ (2007). The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103: 77-87.
22. Mague SD, Blendy JA (2010). OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108: 172-182.
23. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA (2009). Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci USA 106: 10847-10852.
24. McNair D, Lorr M, Droppleman I (1992). EdITS Manual for the Profile of Mood States. Educational and Industrial Testing Service (EdITS): San Diego.
25. Melzack R, Torgerson WS (1971). On the language of pain. Anesthesiology 34: 50-59.
26. Narendran R, Martinez D (2008). Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse 62: 851-869.
27. Nestler EJ (2005). Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445-1449.
28. Norris CJ, Larsen JT, Cacioppo JT (2007). Neuroticism is associated with larger and more prolonged electrodermal responses to emotionally evocative pictures. Psychophysiology 44: 823-826.
29. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J (2006). The mu-opioid receptor gene polymorphism 118A4G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 16: 625-636.
30. Oroszi G, Goldman D (2004). Alcoholism: genes and mechanisms. Pharmacogenomics 5: 1037-1048.
31. Panksepp J, Beatty WW (1980). Social deprivation and play in rats. Behav Neural Biol 30: 197-206.
32. Pecina M, Azhar H, Love TM, Lu T, Fredrickson BL, Stohler CS et al (2012a). Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacology 38: 639-646.
33. Pecina M, Azhar H, Love TM, Lu T, Fredrickson BL, Stohler CS et al (2013a). Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacology 38: 639-646.
34. Pecina M, Martinez-Jauand M, Hodgkinson C, Stohler CS, Goldman D, Zubieta JK (2014). FAAH selectively influences placebo effects. Mol Psychiatry 19: 385-391.
35. Pecina M, Stohler CS, Zubieta JK (2012b). Role of mu-opioid system in the formation of memory of placebo responses. Mol Psychiatry 18: 135-137.
36. Pecina M, Stohler CS, Zubieta JK (2013b). Neurobiology of placebo effects: expectations or learning? Soc Cogn Affect Neurosci 9: 1013-1021.
37. Prossin AR, Love TM, Koeppe RA, Zubieta JK, Silk KR (2010). Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry 167: 925-933.
38. Pruessner JC, Champagne F, Meaney MJ, Dagher A (2004). Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 24: 2825-2831.
39. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C et al (2011). Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA 108: 9268-9273.
40. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK (2007). Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55: 325-336.
41. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK (2008). Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 65: 220-231.
42. Shoji Y, Delfs J, Williams JT (1999). Presynaptic inhibition of GABA(B)-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal. J Neurosci 19: 2347-2355.
43. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R et al (2008). A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109: 520-526.
44. Stohler CS, Kowalski CJ (1999). Spatial and temporal summation of sensory and affective dimensions of deep somatic pain. Pain 79: 165-173.
45. Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT (2009). Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain 5: 32.
46. Taylor KS, Anastakis DJ, Davis KD (2010). Chronic pain and sensorimotor deficits following peripheral nerve injury. Pain 151: 582-591.
47. Wang YJ, Huang P, Ung A, Blendy JA, Liu-Chen LY (2012). Reduced expression of the mu opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience 205: 178-184.
48. Watson D, Clark LA, Tellegen A (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54: 1063-1070.
49. Way BM, Taylor SE, Eisenberger NI (2009). Variation in the muopioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc Natl Acad Sci USA 106: 15079-15084.
50. Weerts EM, McCaul ME, Kuwabara H, Yang X, Xu X, Dannals RF et al (2013). Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. Int J Neuropsychopharmacol 16: 47-53.
51. Zadina JE, Hackler L, Ge LJ, Kastin AJ (1997). A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386: 499-502.
52. Zald DH, Boileau I, El-Dearedy W, Gunn R, McGlone F, Dichter GS et al (2004). Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci 24: 4105-4112.
53. Zhang X, Ashton-Miller JA, Stohler CS (1993). A closed-loop system for maintaining constant experimental muscle pain in man. IEEE Trans Biomed Eng 40: 344-352.
54. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005). Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280: 32618-32624.
55. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA et al (2005). Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 25: 7754-7762.
56. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y et al (2003a). COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299: 1240-1243.
57. Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA et al (2003b). Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen psychiatry 60: 1145-1153.
58. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM et al (2001). Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293: 311-315.